Autolus Therapeutics (NASDAQ:AUTL) Announces Earnings Results, Beats Estimates By $0.10 EPS

Autolus Therapeutics (NASDAQ:AUTL – Get Rating) released its quarterly earnings data on Thursday. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.10, Fidelity Earnings reports. Autolus Therapeutics had a negative net margin of 6,098.54% and a negative return on equity of 49.80%. During the same period last year, the business posted ($0.53) earnings per share.

Shares of NASDAQ AUTL traded down $0.42 during midday trading on Friday, hitting $2.84. 269,657 shares of the company traded hands, compared to its average volume of 250,729. Autolus Therapeutics has a 12-month low of $2.83 and a 12-month high of $8.23. The stock has a 50-day moving average price of $3.89 and a 200 day moving average price of $4.78.

A number of research analysts have recently commented on the stock. Zacks Investment Research lowered shares of Autolus Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, February 21st. William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a research report on Thursday, March 10th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Autolus Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $11.75.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. grew its holdings in Autolus Therapeutics by 214.5% in the fourth quarter. BlackRock Inc. now owns 471,733 shares of the company’s stock worth $2,448,000 after purchasing an additional 321,761 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Autolus Therapeutics by 172.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 153,421 shares of the company’s stock valued at $796,000 after buying an additional 97,030 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Autolus Therapeutics during the fourth quarter valued at approximately $88,000. Legal & General Group Plc grew its holdings in shares of Autolus Therapeutics by 12.8% during the fourth quarter. Legal & General Group Plc now owns 32,704 shares of the company’s stock valued at $170,000 after buying an additional 3,720 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Autolus Therapeutics during the fourth quarter valued at approximately $85,000. Institutional investors and hedge funds own 61.45% of the company’s stock.

Autolus Therapeutics Company Profile (Get Rating)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.

Recommended Stories